RVMD ▲ +0.4% - Revolution Medicines, Inc.
$RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
05-OCT-2026 08:00 AM ET
Share this post
More filings for $RVMD
RVMD ▲ +0.8% - Revolution Medicines, Inc.Oct 23, 2026RVMD ▼ -1.2% - Revolution Medicines, Inc.Oct 21, 2026RVMD ▲ +0.7% - Revolution Medicines, Inc.Oct 20, 2026RVMD ▼ -6.3% - Revolution Medicines, Inc.Oct 8, 2026RVMD ▼ -6.3% - Revolution Medicines, Inc.Oct 8, 2026RVMD ▼ -0.6% - Revolution Medicines, Inc.Sep 15, 2026
View full $RVMD filing history →💬 Comments
Loading comments…
Leave a comment